Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC44A3 pseudogene 1 (SLC44A3P1) is a pseudogene—a genomic DNA sequence similar to a known gene but typically non-functional due to mutations or disruptions in coding or regulatory regions. It is related to the SLC44A3 gene, which encodes a transmembrane transporter, but there is no evidence that SLC44A3P1 encodes a functional protein or plays a direct role in disease, biological pathways, or as a therapeutic target[2][5]. Explanation and context: - SLC44A3P1 is annotated as a pseudogene, meaning it is not expected to produce a functional protein product[2][5]. - There is no evidence in current public resources that SLC44A3P1 has any biological activity, disease associations, or is considered a therapeutic target. - SLC44A3, the parent gene family, codes for a member of the solute carrier family involved in transmembrane transport, but SLC44A3P1 itself lacks functionality and is not listed as a drug target[1][2][3]. - Key fields such as biological_functions, disease_roles, interacting_drugs, mechanism_of_action, biomarkers, and safety_concerns are null due to the pseudogene status and absence of functional data. - The name is accurately specified, and this entry follows conventions for pseudogenes and their abbreviations. - is_incorrect is marked true because SLC44A3P1 is not considered a valid clinical, therapeutic, or functional target; it is a non-functional pseudogene, not a protein-coding, regulatory, or druggable entity. If you are seeking information on a functional, druggable member of the SLC44A3 family, refer instead to "Solute carrier family 44 member 3" (SLC44A3), which is a transporter and an active protein-coding gene[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SLC44A3 pseudogene 1 (SLC44A3P1).